Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide

Fig. 2

Correlation between HLA-A2 or A24 expression and preexisting immunity to AE36 with PFS. HLA-A2+ patients had no significant difference in mPFS compared to HLA-A2− patients (a). However, HLA-A24+ patients showed a trend for increased mPFS compared to HLA-A24− patients (b). HLA-A2+ patients with high preexisting immunity had statistically significant longer mPFS than HLA-A2+ patients with low preexisting immunity. HLA-A2− patients with high preexisting immunity showed a strong trend for longer mPFS than HLA-A2− patients with low preexisting immunity (c). HLA-A24+ patients with high preexisting immunity had a strong trend for longer mPFS compared to HLA-A24+ patients with low preexisting immunity. HLA-A24− patients with high preexisting immunity showed statistically significant longer mPFS compared to HLA-A24− patients with low preexisting immunity (d)

Back to article page